Shares of GRIFOLS S A/S (NASDAQ:GRFS) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.75.
A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. lowered shares of Sogou from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $5.50 to $4.12 in a research report on Thursday, June 27th. BidaskClub upgraded shares of Workhorse Group from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. Finally, Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Tuesday, July 16th.
A number of large investors have recently made changes to their positions in GRFS. Deutsche Bank AG grew its position in GRIFOLS S A/S by 670.3% in the fourth quarter. Deutsche Bank AG now owns 12,427,277 shares of the biotechnology company’s stock worth $228,164,000 after acquiring an additional 10,813,901 shares in the last quarter. Norges Bank purchased a new position in GRIFOLS S A/S in the fourth quarter worth $57,748,000. JPMorgan Chase & Co. grew its position in GRIFOLS S A/S by 856.0% in the first quarter. JPMorgan Chase & Co. now owns 1,558,478 shares of the biotechnology company’s stock worth $31,340,000 after acquiring an additional 1,395,461 shares in the last quarter. FIL Ltd grew its position in GRIFOLS S A/S by 12.2% in the first quarter. FIL Ltd now owns 8,170,942 shares of the biotechnology company’s stock worth $164,318,000 after acquiring an additional 887,474 shares in the last quarter. Finally, Impax Asset Management Group plc grew its position in GRIFOLS S A/S by 1,557.5% in the fourth quarter. Impax Asset Management Group plc now owns 482,189 shares of the biotechnology company’s stock worth $8,853,000 after acquiring an additional 453,098 shares in the last quarter. Institutional investors own 19.01% of the company’s stock.
GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, meeting analysts’ consensus estimates of $0.25. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. Equities analysts anticipate that GRIFOLS S A/S will post 1.27 EPS for the current fiscal year.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Read More: CD Ladder
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.